Newron Pharmaceuticals SpA (NWRN) — Cash Flow Quality Index
Newron Pharmaceuticals SpA (NWRN) has a Cash Flow Quality Index of -0.28x as of December 2024. Operating cash flow of CHF-8.79 Million is below net income of CHF30.95 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore cash efficiency ratio of Newron Pharmaceuticals SpA to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Newron Pharmaceuticals SpA Cash Flow Quality Index (2024–2024)
Historical Cash Flow Quality Index for Newron Pharmaceuticals SpA across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check NWRN total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Newron Pharmaceuticals SpA (2024–2024)
Year-by-year earnings quality comparison for Newron Pharmaceuticals SpA. For live market cap and the full company financial profile, see NWRN stock market capitalisation.
| Year | Quality Index | Operating CF (CHF) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -0.82x | CHF-17.61 Million | CHF21.39 Million | — |